Biologics in pediatric Crohn's disease: Is it time to move to an earlier therapeutic approach?

Expert Review of Clinical Immunology

Volumn 10, Issue 11, 2014, Pages 1423-1426

  Hyams, Jeffrey S ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

anti TNFa; biological therapy; children; Crohn's disease; immunomodulators; risk stratification

Indexed keywords

IMMUNOMODULATING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; CLINICAL DECISION MAKING; CROHN DISEASE; DISEASE COURSE; EVIDENCE BASED MEDICINE; HUMAN; OUTCOME ASSESSMENT; PEDIATRICS; REVIEW; RISK FACTOR; TREATMENT RESPONSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHILD; IMMUNOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911463575     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.955017     Document Type: Review

References (27)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78
2. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6
3. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97:947-53
4. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139:1147-55
5. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008; 6(10):1105-11
6. Cotter J, Dias de Castro F, Moreira MJ, et al. Tailoring Crohn's disease treatment: The impact of small bowel capsule endoscopy. J Crohns Colitis 2014. [Epub ahead of print]
7. Weersma RK, Stokkers PC, van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009;58:388-95
8. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014;15:382-92
9. Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis 2014;20:978-86
10. Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010;16:2090-8
11. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7
12. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
13. Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014;146:383-91
14. Siegel CA, Siegel LS, Hyams JS, et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011;17:30-8
15. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415-22
16. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7
17. Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145: 766-74; e1
18. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25
19. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8; e1-5
20. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30
21. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146:681-8; e1
22. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-22
23. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT Registry. Am J Gastroenterol 2014;109:212-23
24. Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014;146:941-9
25. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94
26. Moran GW,DubeauMF, Kaplan GG, et al. Phenotypic features of Crohn's disease associated with failure of medical treatment. Clin Gastroenterol Hepatol 2014;12: 434-42; e1
27. Scott FI, Lichtenstein GR. Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2014;12:59-75